Haemonetics Corporation
HAE
Positions held
Your positionsHAE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Haemonetics Corporation is well-positioned in the medical devices industry, benefiting from a growing demand for blood management solutions as healthcare systems prioritize efficiency and patient outcomes.
- In the most recent quarter, Haemonetics reported a gross margin of 59.8%, an improvement from 57.2% in the prior quarter.
- The company's operating margin expanded to 16.9%, indicating improved operational efficiency.
- Despite its strengths, Haemonetics faces challenges with a high debt-to-equity ratio of 140.27, which may limit financial flexibility.
- The company's revenue decreased by 2% compared to the prior quarter, falling from $346 million to $339 million.
- Haemonetics' net income turned negative in the first quarter of 2026, reporting a loss of $20.147 million.
Fundamentals
| Market cap | $5.44B | Enterprise value | $6.39B | Trailing P/E | 57.71 | Forward P/E | 20.53 |
| PEG | 1.61 | Price / book | 6.49 | Beta | 0.61 | Dividend yield | 0.00% |
| Revenue growth | 5.6% | Earnings growth | 2.9% | Gross margin | 59.3% | Operating margin | 17.9% |
| Profit margin | 7.1% | ROE | 11.2% | ROA | 6.6% | Debt / equity | 1.40 |
| Current ratio | 3.08 | Free cash flow | $312.84M | Analyst recommendation | buy | Mean target | $118.00 |
| 52w high | $121.00 | 52w low | $48.17 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $339M | $346M | $339M | $327M | $321M |
| Op margin | 16.9% | 15.1% | 20.1% | 20.5% | 16.8% |
| Net income | $33.0M | -$20.1M | $44.7M | $38.7M | $34.0M |
| Gross margin | 59.8% | 57.2% | 59.7% | 59.5% | 59.8% |
| Gross profit | $203M | $198M | $202M | $195M | $192M |
| Operating income | $57.5M | $52.3M | $68.1M | $67.1M | $53.9M |
- Revenue -2% vs prior quarter ($339M vs $346M).
- Gross margin 59.8% (was 57.2% prior quarter).
- Operating margin expanded to 16.9%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.4B | $1.3B | $1.2B | — |
| Op margin | 18.1% | 14.8% | 13.4% | 13.3% | — |
| Net income | $97.3M | $168M | $118M | $115M | — |
| Gross margin | 59.0% | 55.0% | 52.8% | 52.6% | — |
| Gross profit | $788M | $749M | $692M | $615M | — |
| Operating income | $241M | $201M | $175M | $156M | — |
Headlines — watch
• [WARN · legal] 3 Cash-Producing Stocks Walking a Fine Line
News
2026-10-09 · 3 Cash-Producing Stocks Walking a Fine Line
2026-10-09 · Haemonetics (HAE) Jumped, What Is Behind The Move?
2026-10-08 · Haemonetics (HAE) Shares Skyrocket, What You Need To Know
2026-10-08 · Top Midday Gainers
2026-10-08 · HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
2026-10-08 · Chipotle, Starbucks, Palantir, Intel, SpaceX, Wolfspeed, and More Stocks That Explain Today’s Market
2026-10-08 · Haemonetics Says CSL Plasma to Complete Rollout of Products by End-2027
2026-10-08 · Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
2026-10-08 · Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers
2026-10-08 · Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
2026-10-08 · Haemonetics stock surges 17% on CSL Plasma supply deal update
2026-10-05 · PAHC vs. HAE: Which Stock Is the Better Value Option?
Price (daily)
Full chart · RSI · MACD · patternsOn Trade and Ticker